证券代码：301166 证券简称：优宁维 公告编号：2025-080 上海优宁维生物科技股份有限公司 关于召开 2025 年第三次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 3、会议召开的合法、合规性：公司第四届董事会第八次会议审议通过了《关 于召开 2025 年第三次临时股东大会的议案》，本次股东大会的召开符合有关法 律、行政法规、部门规章、规范性文件和《公司章程》的规定。 4、会议召开日期、时间： 现场会议召开时间：2025 年 10 月 16 日（星期四）下午 14:30。 网络投票时间：2025 年 10 月 16 日（星期四） 其中，通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 10 月 16 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通过深圳证券交易 所互联网系统投票的具体时间为 2025 年 10 月 16 日 9:15-15:00 期间的任意时间。 5、会议的召开方式：现场投票表决与网络投票相结合的方式，本次股东大 会将通过深交所交易系统和互联网投票系统向全体 ...

证券代码：301166 证券简称：优宁维 公告编号：2025-077 上海优宁维生物科技股份有限公司 第四届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、会议召开情况 上海优宁维生物科技股份有限公司（以下简称"公司"）第四届监事会第八次 会议（以下简称"本次会议"）于 2025 年 9 月 28 日在公司会议室以现场结合通讯 的方式召开。会议通知已于 2025 年 9 月 19 日以电子邮件方式送达全体监事。会 议应出席的监事 3 人，实际出席会议的监事 3 人，本次会议由监事会主席王艳女 士主持。本次会议的召集、召开和表决程序符合法律、法规及《公司章程》的规 定。 表决结果：3 票赞成，0 票反对，0 票弃权。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《关于修 订<公司章程>并办理工商变更登记备案的公告》。 本议案尚需提交股东大会审议。 二、会议审议情况 1、审议并通过《关于续聘 2025 年度会计师事务所的议案》 经审议，公司监事会认为：立信中联会计师事务所（特殊普通合伙）在执业 过程中坚 ...

证券代码：301166 证券简称：优宁维 公告编号：2025-076 上海优宁维生物科技股份有限公司 第四届董事会第八次会议决议公告 一、会议召开情况 上海优宁维生物科技股份有限公司（以下简称"公司"）第四届董事会第八次 会议（以下简称"本次会议"）于 2025 年 9 月 28 日以现场结合通讯方式召开。会 议通知已于 2025 年 9 月 19 日以电子邮件方式送达全体董事。会议应出席的董事 9 人，实际出席会议的董事 9 人。本次会议由董事长冷兆武先生主持，公司高管 及监事列席会议。本次会议的召集、召开和表决程序符合法律、法规及《公司章 程》的规定。 二、会议审议情况 1、审议并通过《关于续聘 2025 年度会计师事务所的议案》 经审议，公司董事会同意续聘立信中联会计师事务所（特殊普通合伙）为公 司 2025 年度的审计机构，为公司 2025 年度提供财务报告和内部控制审计服务， 聘期为一年，并同意将该议案提交股东大会审议。 表决结果：9 票赞成，0 票反对，0 票弃权。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《关于续 聘 2025 年度会计师事务所的公告》。 本公 ...

Group 1 - The core viewpoint of the news is that You Ning Wei's stock performance and financial metrics indicate a challenging period, with a decline in revenue and net profit, while financing activities show a relatively high level of engagement [1][2]. Group 2 - On September 25, You Ning Wei's stock price fell by 1.17%, with a trading volume of 31.80 million yuan. The financing buy-in amount was 2.18 million yuan, while the financing repayment was 1.93 million yuan, resulting in a net financing buy of 250,600 yuan. The total financing and securities balance reached 61.66 million yuan [1]. - The financing balance of You Ning Wei is 61.66 million yuan, accounting for 2.34% of the circulating market value, which is above the 70th percentile level over the past year, indicating a high position [1]. - As of June 30, the number of shareholders of You Ning Wei increased to 11,400, a rise of 5.02%, with an average of 4,994 circulating shares per person, up by 31.33% [2]. - For the first half of 2025, You Ning Wei reported operating revenue of 505 million yuan, a year-on-year decrease of 8.63%, and a net profit attributable to shareholders of -13.38 million yuan, a year-on-year decrease of 188.64% [2]. - Since its A-share listing, You Ning Wei has distributed a total of 182 million yuan in dividends, with 138 million yuan distributed over the past three years [3].

Core Insights - The light lithography machine concept sector has seen significant stock price increases, with 100 out of 105 stocks rising this year, averaging a 49.18% increase [1] - The light lithography machine is a critical device in wafer manufacturing, with low current domestic production rates, but notable progress has been made since the implementation of the "02 Special" project in 2009 [1][2] - The semiconductor industry's recovery and the demand for advanced process capacity driven by artificial intelligence are key factors contributing to the market's interest in light lithography machines [2] Company Performance - United Chemical has the highest stock price increase at 346.74% this year, with a net profit of 34 million yuan, up 21.62% year-on-year [3] - Kai Mei Teqi has seen a stock price increase of 207.83%, with a net profit of 55.84 million yuan, reflecting a significant year-on-year growth of 199.82% [3][4] - Tengjing Technology and Kent Catalysis also reported substantial stock price increases of 186.67% and 180.20%, respectively, with net profits of 37 million yuan and 39 million yuan [3] Industry Trends - The international semiconductor industry association predicts that capital expenditure for advanced process equipment will surge to over $50 billion by 2028, a 94% increase from $26 billion in 2024, with a compound annual growth rate of 18% [2] - The Ministry of Industry and Information Technology's 2024 guidance includes domestic KrF and ArF lithography machines, indicating progress in DUV lithography machine technology [1]

Core Insights - The company participated in a collective reception day and mid-year performance briefing, emphasizing its commitment to value communication and future confidence [1] Group 1: R&D and Product Development - The company has been continuously investing in R&D in the antibody field, leading to a rich portfolio of raw material antibodies and protein products [1] - As of mid-2025, the company's Hangzhou antibody R&D center has developed over 4,200 SPUs, while the Nanjing protein R&D center has developed over 1,800 SPUs [1] Group 2: Brand Growth and Revenue - The company’s self-owned brand products, including Absin, LabEx, STARTER, and UA, achieved over 20% growth in the previous year, contributing to an increased share of self-owned brand revenue [1]

Group 1: Company Strategy and Performance - The company emphasizes strategies to boost stock prices and performance through enhanced operational capabilities and market confidence [2] - Two share repurchase plans have been launched to support stock price stability and investor confidence [2] - The company aims to improve customer service and market competitiveness through both organic growth and external acquisitions [2] Group 2: Product Development and Market Recognition - The company has significantly increased its product offerings in the antibody and recombinant protein sectors, with over 4,200 products developed at the Hangzhou center and over 1,800 at the Nanjing center as of mid-2025 [3] - Self-owned brand products have achieved over 20% growth compared to the previous year, with an increasing revenue share from these brands [3] Group 3: Financial Performance and Challenges - In the first half of 2025, the company reported a revenue of 1.5 billion, maintaining a similar level to 2024, but faced a net profit loss due to market demand issues and increased competition [3] - The company’s gross margin has been under pressure, and while self-owned brands are growing rapidly, their overall revenue contribution remains low, delaying significant improvements in overall profitability [3] - The company is closely monitoring stock price fluctuations and plans to continue share repurchase activities in response to market conditions [3]

Financial Performance - In the first half of 2025, the company reported operating revenue of 505 million yuan, a decrease of 8.63% year-on-year [1][2] - The net profit attributable to shareholders was -13.38 million yuan, representing a decline of 188.64% compared to the same period last year [2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was -20.68 million yuan, a significant drop of 1,858.69% year-on-year [2] - The net cash flow from operating activities was -61.54 million yuan, a decrease of 149.14% compared to the previous year [2] Historical Financial Data - From 2021 to 2024, the company's operating revenue was 1.11 billion yuan, 1.20 billion yuan, 1.22 billion yuan, and 1.12 billion yuan respectively [2] - The net profit attributable to shareholders for the same years was 109 million yuan, 107 million yuan, 40.32 million yuan, and 10.15 million yuan [2] - The net profit after deducting non-recurring gains and losses for the years was 102 million yuan, 85.30 million yuan, 12.29 million yuan, and -1.51 million yuan [2] Stock Market Performance - The company was listed on the Shenzhen Stock Exchange's ChiNext on December 28, 2021, with an initial public offering of 21.67 million shares at a price of 86.06 yuan per share [3] - The stock reached a peak price of 136 yuan on the second day of trading but has since experienced a decline, currently trading below the initial offering price [4] - The total funds raised from the IPO amounted to 1.865 billion yuan, with a net amount of 1.596 billion yuan after deducting issuance costs [4] Use of IPO Proceeds - The company planned to use the raised funds for online marketing network and information technology construction, offline marketing and service network upgrades, research and development center construction, and to supplement working capital [4]

Group 1: Company Overview - The company, Shanghai Youningwei Biotechnology Co., Ltd., reported a gross margin of approximately 50% for its proprietary brands, with a revenue growth of over 20% year-on-year in the first half of 2025 [1] - The revenue share of proprietary brands is expected to continue increasing as the company invests more in sales resources and expands its product pipeline [1] Group 2: Profitability and Sales Strategy - The gross margin for agency business is facing short-term downward pressure, but long-term prospects suggest a rationalization of margins with potential for rebound as the industry evolves [1] - The company maintains a direct sales model, which involves significant barriers such as marketing team management, high direct sales costs, and pressure on accounts receivable [1] Group 3: Market Position and Client Services - The company has developed a comprehensive service system that supports clients throughout the sales process, including product selection, training, technical support, and after-sales service [2] - The client base primarily consists of research institutions, which leads to higher accounts receivable due to reimbursement payment structures; however, the company manages this risk through effective accounts receivable control [2] Group 4: Future Plans and Market Strategy - The company plans to enhance its product offerings and expand both proprietary and third-party brands to meet diverse customer needs [2] - A share repurchase plan was initiated in 2024, with a total of 25,987,076 shares repurchased for employee stock ownership plans [2] - The company aims to leverage its 20 years of experience in life sciences to provide integrated solutions that enhance sales efficiency and customer loyalty [2]

Group 1 - The core viewpoint of the news is that You Ning Wei's stock performance and financial metrics indicate a challenging period, with a decline in revenue and net profit, alongside significant financing activity [1][2]. - As of September 15, You Ning Wei's stock price decreased by 0.41%, with a trading volume of 22.94 million yuan. The financing buy-in amount was 2.10 million yuan, while the financing repayment was 2.96 million yuan, resulting in a net financing outflow of 0.86 million yuan [1]. - The total margin trading balance for You Ning Wei reached 59.21 million yuan, accounting for 2.16% of its market capitalization, indicating a relatively high level compared to the past year [1]. Group 2 - As of June 30, You Ning Wei had 11,400 shareholders, an increase of 5.02% from the previous period, with an average of 4,994 circulating shares per shareholder, up by 31.33% [2]. - For the first half of 2025, You Ning Wei reported a revenue of 505 million yuan, a year-on-year decrease of 8.63%, and a net profit attributable to shareholders of -13.38 million yuan, a decline of 188.64% [2]. - Since its A-share listing, You Ning Wei has distributed a total of 182 million yuan in dividends, with 138 million yuan distributed over the past three years [3].